Global Media Contacts:
Christine Lydon
+44-20-7395-7145
christine.lydon@fleishmaneurope.com

Iva Ng
OrbusNeich
+852 3109-7268
ing@orbusneich.com

COMBO™ Dual Therapy Stent Receives CE Mark for 38mm Lengths

Offering physicians greater flexibility in coronary treatment

HONG KONG, [10 April 2015] – OrbusNeich has received CE mark for the 38mm length of its COMBO Dual Therapy Stent portfolio for the treatment of coronary artery disease.

The new configurations of 3.0 – 4.0 mm diameter by 38mm length are expected to provide physicians with more choices to treat longer lesions during interventional heart procedures and provide additional benefits from cost and clinical perspectives (less number of stents and avoidance of stent overlapping with multiple stent use), as well as possible shortened procedural time.

The extended lengths will continue to address the challenges of delayed healing, as seen in monotherapy drug eluting stents, by facilitating benefits associated with earlier healing as well as long-term clinical stability.

The COMBO Stent received CE mark in May 2013 and is the world's only drug eluting stent with active endothelial progenitor cell (EPC) capture technology that accelerates endothelial coverage and controls both restenosis and neointimal proliferation.

"Since its launch, the COMBO Stent has played an important role in helping patients with coronary artery disease," said president and chief executive officer, Wayne Johnson. "The COMBO Stent, with its unique pro-healing properties and the addition of the new 38mm length configurations offers physicians greater flexibility in the treatment of coronary disease. This is another example of OrbusNeich's commitment to provide innovative best in class devices to our physicians and their patients."

COMBO Dual Therapy Stent - Repair, Regenerate, Naturally

COMBO is the world's first and only dual therapy stent designed to repair vessel injury and regenerate endothelium, fostering natural, true vessel healing. It does this by accelerating endothelial coverage and controlling neo-intimal proliferation. This is done through a combination of the proven EPC capturing technology and a sirolimus drug elution, delivered from a bioresorbable polymer that is completely degraded within 90 days.

OrbusNeich's patented EPC capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first dual therapy stent, the COMBO Dual Therapy Stent, and the world's first pro-healing stent, the Genous™ Stent. Other products include stents and balloons marketed under the names of Azule™, R Stent™, Scoreflex™, Sapphire™, Sapphire™, II and Sapphire™ II NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.

Follow OrbusNeich on Twitter at www.twitter.com/OrbusNeich, and learn more about the company and its innovative technology on OrbusNeich's YouTube Channel: http://www.youtube.com/user/OrbusNeichMedia.

###